Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kipps, Thomas J. [1 ]
Swinnen, Lode J. [2 ]
Wierda, William G. [3 ]
Jones, Jeffrey Alan [4 ]
Coutre, Steven E. [5 ,6 ,7 ]
Smith, Mitchell R. [8 ]
Yang, Jainning [9 ]
Cui, Yue [9 ]
Busman, Todd [9 ]
Enschede, Sari [9 ]
Humerickhouse, Rod [9 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Johns Hopkins Univ, Sch Med, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[4] Ohio State Univ, Columbus, OH 43210 USA
[5] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA
[6] Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA
[7] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[8] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[9] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1669 / 1669
页数：1
相关论文
共 50 条
  • [41] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Keating, Michael J.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Sargent, Rachel L.
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    BLOOD, 2011, 118 (21) : 448 - 448
  • [42] Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study
    Shadman, Mazyar
    Gopal, Ajay K.
    Press, Oliver
    Maloney, David G.
    Mawad, Raya
    Wadsworth, Troy
    Dennie, Trevor W.
    Schultheiss, Karl
    Kojouri, Kiarash
    Kammerer, Britt E.
    Pagel, John M.
    BLOOD, 2016, 128 (22)
  • [43] Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia
    Ferrajoli, Alessandra
    Faderl, Stefan
    O'Brien, Susan
    Wierda, William
    Ayala, Ana
    Smith, Susan
    Brown, Tiffany C.
    Kantarjian, Hagop
    Keating, Michael
    BLOOD, 2008, 112 (11) : 1088 - 1088
  • [44] Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL)
    Kovacs, G.
    Bahlo, J.
    Kluth, S.
    Fink, A. M.
    Cramer, P.
    von Tresckow, J.
    Maurer, C.
    Langerbeins, P.
    Gross-Opphoff-Mueller, C.
    Fischer, K.
    Wendtner, C. -M.
    Kreuzer, K. -A.
    Stilgenbauer, S.
    Hallek, M.
    Eichhorst, B.
    Goede, V.
    Oncology Research and Treatment, 2015, 38 : 91 - 91
  • [45] ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Wilson, W.
    O'Connor, O. O.
    Roberts, A. W.
    Czuczman, M.
    Brown, J.
    Xiong, H.
    Xiong, H.
    Chiu, Y.
    Krivoshik, A.
    Enschede, S.
    Humerickhouse, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, Rituximab combination (FCR) in chronic lymphocytic leukemia (CLL).
    Keating, M
    Manshouri, T
    O'Brien, S
    Wierda, W
    Kantarjian, H
    Washington, L
    Lerner, S
    Albitar, M
    BLOOD, 2002, 100 (11) : 205A - 205A
  • [47] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Stilgenbauer, Stephan
    Bahlo, Jasmin
    Schweighofer, Carmen D.
    Boettcher, Sebastian
    Staib, Peter
    Kiehl, Michael
    Eckart, Michael J.
    Kranz, Gabriele
    Goede, Valentin
    Elter, Thomas
    Buehler, Andreas
    Winkler, Dirk
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
  • [48] Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).
    Batty, Nicolas
    Badoux, Xavier C.
    Keating, Michael
    Lin, E.
    Lerner, Susan
    O'Brien, Susan
    Ferrajoli, Alessandra
    Kadia, Tapan
    Burger, Jan A.
    Faderl, Stefan
    Wierda, William G.
    BLOOD, 2009, 114 (22) : 1339 - 1340
  • [49] Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)
    Obrtlikova, Petra
    Jonasova, Anna
    Siskova, Magda
    Cmunt, Eduard
    Berkova, Adela
    Karban, Josef
    Svackova, Katerina
    Trneny, Marek
    BLOOD, 2012, 120 (21)
  • [50] Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Fraser, Graeme
    Chanan-Khan, Asher
    Demirkan, Faith
    Silva, Rodrigo Santucci
    Grosicki, Sebastian
    Janssens, Ann
    Mayer, Jiri
    Bartlett, Nancy
    Dilhuydy, Marie Sarah
    Loscertales, Javier
    Avigdor, Abraham
    Rule, Simon
    Samoilova, Olga
    Pavlosky, Miguel
    Hallek, Michael
    Salman, Mariya
    Tamegnon, Monelle
    Sun, Steven
    Connor, Anne
    Nottage, Kerri
    Balasubramanian, Sriram
    Howes, Angela
    Cramer, Paula
    LEUKEMIA & LYMPHOMA, 2020, 61 : 106 - 108
12345